Pub. Date : 2017 Sep 1
PMID : 28600475
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Our aim was to determine the therapeutic efficacy of simultaneously targeting these pathways in thyroid cancer with a single agent and to evaluate biomarkers of treatment response.Experimental Design: CUDC-907 is a first-in-class compound, functioning as a dual inhibitor of HDACs and the PI3K/AKT pathway. | CUDC-907 | thymoma viral proto-oncogene 1 | Mus musculus |
| 2 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | cyclin B1 | Mus musculus |
| 3 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | aurora kinase A | Mus musculus |
| 4 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | aurora kinase B | Mus musculus |
| 5 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | polo like kinase 1 | Mus musculus |
| 6 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | cyclin-dependent kinase inhibitor 1A (P21) | Mus musculus |
| 7 | We investigated its antiproliferative effect in vitro and in vivoResults: CUDC-907 significantly inhibited cellular proliferation in thyroid cancer cell lines, induced G2-M arrest with decreased levels of the checkpoint regulators cyclin B1, AURKA, AURKB, PLK1, and increased p21 and p27. | CUDC-907 | cyclin-dependent kinase inhibitor 1B | Mus musculus |
| 8 | CUDC-907 treatment caused H3 hyperacetylation and decreased HDAC2 expression. | CUDC-907 | histone deacetylase 2 | Mus musculus |
| 9 | CUDC-907 treatment reduced both p-AKT and p-ERK1/2 levels. | CUDC-907 | thymoma viral proto-oncogene 1 | Mus musculus |